Trial Profile
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 08 Mar 2019 Status changed from active, no longer recruiting to completed, according to the results published in the Investigational New Drugs
- 08 Mar 2019 Results published in the Investigational New Drugs
- 18 Dec 2018 Status changed from recruiting to active, no longer recruiting.